Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)

Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines




Julkaisun tekijät: Feuth Thijs, Patovirta Riitta Liisa, Grierson Sirkku, Danilovitš, Manfred, Viiklepp Piret, Aaltonen Hanna K, Vauhkonen Mikko, Pehme Lea, Vasankari Tuula

Kustantaja: INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)

Julkaisuvuosi: 2021

Journal: International Journal of Tuberculosis and Lung Disease

Tietokannassa oleva lehden nimi: INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Lehden akronyymi: INT J TUBERC LUNG D

Volyymi: 25

Julkaisunumero: 7

Sivujen määrä: 7

ISSN: 1027-3719

eISSN: 1815-8439

DOI: http://dx.doi.org/10.5588/ijtld.20.0892


Tiivistelmä

BACKGROUND: Multidrug-resistant TB (MDR-TB) is a growing problem in the effort to end the global TB epidemic. In 2019, the WHO adopted a new standardised regiment for MDR-TB, consisting of only oral medications.

METHODS: We estimated the impact of the new guidelines on the costs of TB treatment in Estonia and Finland. For both countries, the costs of the two most common new drug regimens were calculated, including drug costs, as well as care-and monitoring-related costs.

RESULTS: In Turku, Finland, treatment costs with the old regimen were €178,714; this could either increase by 10% or decrease by 18%, depending on the duration of bedaquiline use (6 months vs. 20 months). In Estonia, treatment costs with the old regimen were €33,664, whereas the new regimens were associated with a 40% increase in overall costs.

CONCLUSIONS: The 2019 WHO guidelines have led to significant changes in the costs of MDR-TB treatment in Finland and Estonia. These changes depend mostly on the drug regimen administered and on care-related practices, with important differences between countries and even within the same country due to local practices.


Last updated on 2022-24-01 at 12:54